D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)
D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]
D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock. A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their […]
